Peroxisome proliferator-activated receptor-γ agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty

Metabolism: Clinical and Experimental

Volumn 54, Issue 5, 2005, Pages 590-597

  Wang, Guang ^a   Wei, Jinru ^a   Guan, Youfei ^b   Jin, Nan ^a   Mao, Jieming ^a   Wang, Xian ^a,b  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INSULIN; INSULIN SENSITIZING AGENT; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; ROSIGLITAZONE;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HOMEOSTASIS; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; MALE; MONOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 17844406613     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2004.11.017     Document Type: Article

References (30)

1. Y. Hojo, U. Ikecla, and T. Katsuki Chemokine expression in coronary circulation after coronary angioplasty as a prognostic factor for restenosis Atherosclerosis 156 2001 165 170
2. R. Ross Atherosclerosis-an inflammatory disease N. Engl. J. Med. 340 1999 115 126
3. M. Baggiolini Chemokines and leukocyte traffic Nature 392 1998 565 568
4. T.J. Reape, and P.H. Groot Chemokines and atherosclerosis Atherosclerosis 147 1999 213 225
5. F. Haverkate, S.G. Thompson, and S.D.M. Pyke Production of C-reactive protein and risk of coronary events in stable and unstable angina Lancet 349 1997 462 466
6. M.A. Mendall, P. Patel, and L. Ballam C-reactive protein and its relation to cardiovascular risk factor: a population based cross-sectional study BMJ 312 1996 1061 1065
7. T. Antonucci, R. Whitcomb, and R. Mclain Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone Diabetes Care 20 1997 188 193
8. M.K. Lee, P.D.G. Miles, and M. Khoursheed Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat Diabetes 43 1994 1435 1439
9. N. Marx, H. Duez, and J.C. Fruchart Peroxisome proliferators activated receptors and atherogenesis, regulators of gene expression in vascular cells Circ. Res. 94 2004 1168 1178
10. S.M. Jackson, F. Parhami, and X.P. Xi Peroxisome proliferators-activated receptors activators target human endothelial cell to inhibit leukocyte-endothelial cell interaction Arterioscler. Thromb. Vasc. Biol. 19 1999 2094 2104
11. V. Pasceri, H.D. Wu, and J.T. Willerson Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferators-activated receptors-γ activators Circulation 101 2000 235 238
12. C. Jiang, A.T. Ting, and B. Seed PPAR-γ agonists inhibit production of monocyte inflammatory cytokines Nature 391 1998 82 86
13. X. Zeng, J. Dai, and D. Remick Homocysteine mediated expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human monocytes Circ. Res. 93 2003 311 320
14. N. Marx, J. Froehlich, and L. Siam Antidiabetic PPARγ-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease Arterioscler. Thromb. Vasc. Biol. 23 2003 283 288
15. S.M. Haffner, A.S. Greenberg, and W.M. Weston Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus Circulation 106 2002 679 684
16. T.M. Larsen, S. Toubro, and A. Astrup PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy? Int. J. Obes. Relat. Metab. Disord. 27 2003 147 161
17. N.A. Nelken, S.R. Coughlin, and D. Gordon Monocyte chemoattractant protein-1 in human atheromatous plaques J. Clin. Invest. 88 1991 1121 1127
18. G. Liuzzo, D.J. Angiolillo, and A. Buffon Enhanced response of blood monocytes to in vitro LPS-challenge in patients with recurrent unstable angina Circulation 103 2001 2236 2241
19. V. Pasceri, J. Chang, and J.T. Willerson Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs Circulation 103 2001 2531 2534
20. N. Marx, U. Schonbeck, and M.A. Lazar Peroxisome proliferators-activated receptors gamma activators inhibit gene expression and migration in human vascular smooth muscle cells Circ. Res. 83 1998 1097 1103
21. N. Marx, G. Sukhova, and C. Murphy Macrophages in human atheroma contain PPAR-γ: differentiation-dependent PPAR-γ expression and reduction of MMP-9 activity through PPAR-γ activation in mononuclear phagocytes in vitro Am. J. Pathol. 153 1998 17 23
22. H. Ginsberg, J. Plutzky, and B.E. Sobel A review of metabolic and cardiovascular effects of oral antidiabetic agents: beyond glucose level slowering J. Cardiovasc. Risk 6 1999 337 346
23. M.K. Lee, P.D.G. Kiles, and M. Khoursheed Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat Diabetes 43 1994 1435 1439
24. H.E. Lebovitz, J.F. Dole, and R. Patwardhan Rosiglitazone monotherapy is effective in patients with type 2 diabetes J. Clin. Endocrinol. Metab. 86 2001 280 288
25. A. Chawla, W.A. Boisvert, and C.H. Lee A PPARγ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis Mol. Cell 7 2001 161 171
26. J.L. Goldstein, and M.S. Brown Regulation of low-density lipoprotein receptors: implications for pathogenesis and therapy of hypercholesterolemia and atherosclerosis Circulation 76 1987 504 507
27. Z. Chen, S. Ishibashi, and S. Perrey Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice, pleiotropic effects on CD36 expression and HDL Arterioscler. Thromb. Vasc. Biol. 21 2001 372 377
28. J.S. Sidhu, Z. Kaposzta, and H.S. Markus Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus Arterioscler. Thromb. Vasc. Biol. 124 2004 930 934
29. J. Minatnikawa, S. Tanaka, and M. Yamauchi Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes J. Clin. Endocrinol. Metab. 83 1998 1818 1820
30. T. Takagi, T. Akasaka, and A. Yamamuro Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus, a serial intravascular ultrasound study J. Am. Coll. Cardiol. 36 2000 1529 1535